摘要
目的探讨卡培他滨联合肝动脉插管化疗栓塞(TACE)在中晚期肝癌患者中的临床应用。方法中晚期肝癌患者随机分为两组,治疗组20例,对照组40例。治疗组采用TACE一周后,服用卡培他滨每日2.0 g/m2,分2次口服,服用2周,停用2周为1个疗程。对照组采用单纯TACE治疗,两组中TACE治疗每月1次。结果治疗组20例患者中完全缓解(CR)0例,部分缓解(PR)13例,无变化(SD)6例,恶化(PD)1例,总有效率为65.0%,甲胎蛋白(AFP)下降率为60.0%,肿瘤缩小率为70.0%,中位生存期为11.5个月。对照组40例患者中,CR0例,PR12例,SD16例,PD12例,总有效率为30.0%,AFP下降率为32.4%,肿瘤缩小率为32.4%,中位生存期为7.6个月。治疗组和对照组手足综合征发生率55.0%和10.0%,骨髓抑制25.0%和22.5%,腹泻15.0%和12.5%,肝脏毒性90.0%和82.5%,以上并发症多为Ⅰ～Ⅱ级,均可耐受,除手足综合征外,其他并发症经过治疗后均恢复正常。结论希罗达联合TACE治疗中晚期肝癌的安全性、疗效,均优于单纯TACE。
Objective To evaluate the clinical efficacy of capecitabine combined with chemoembolization （TACE） for advanced liver cancer. Methods Forty patients with liver cancer were retrospectively divided into two groups ： Treatment group, on the basis of TACE, 20 patients received oral capeeitabine at 2000 mg/m2 , twice - daily for 14 days followed by 7 - day rest period and repeated in every three week intervals for more than two cycles. Control group, 20 patients received TACE only at 1 - month intervals for at least two cycles. Results In capecitabine and TACE group： there were 0 CR, 13 PR, 6 SD and 1 PD; the overall response rate was 65.0% ; the AFP and tumor reduction rates were 60. 0% and 70. 0% ; the median survival time was 11.5 months. In the TACE only group： there were 0 CR, 12 PR, 16 SD and 12 PD; the overall response rate was 30. 0 % ; the AFP and tumor reduction rates were 32. 4% and 32.4 % ; the median survival time was 7.6months. Comparison of complications： the incidence of hand- foot syndrome of the treatment group and the control group was 55.0% and 10. 0% respectively, the incidence of bone barrow suppression of the treatment group and the control group was 25.0% and 22. 5% respectively, the incidence of diarrhea of the treatment group and the control group was 15.0% and 12. 5% respectively, the incidence of liver toxicity of the treatment group and the control group was 90. 0% and 82. 5% respectively, Most of these toxicities were tolerable at grade 1 -2. Conclusion Capecitabine combined with TACE may be safe and effective for advanced liver cancer and superior to single TACE.
出处
《实用心脑肺血管病杂志》
2009年第10期855-857,共3页
Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease
